Apolipoprotein A-1 (ApoA-1)
The ApoA-1 test measures apolipoprotein A-1, the principal protein of HDL particles and the cofactor for reverse cholesterol transport. It quantifies atheroprotective HDL particle number directly, providing cardiovascular risk discrimination beyond HDL cholesterol, particularly when triglycerides are elevated or lipid profiles are discordant.
1
Biomarkers
Blood (serum)
Sample
3–5 business days
Turnaround
Preferred
Fasting
What is the ApoA-1 test?
The Apolipoprotein A-1 test quantifies the major protein constituent of HDL particles, providing a direct measure of the cardioprotective lipoprotein system that HDL cholesterol only approximates. Practitioners order ApoA-1 when standard lipid profiles leave residual uncertainty — when HDL-C appears discordant with clinical risk, when triglycerides are elevated and may artefactually lower HDL-C, or when advanced lipoprotein phenotyping is needed to refine cardiovascular risk stratification and guide therapy. ApoA-1 complements rather than replaces the lipid profile. It is interpreted alongside ApoB (the atherogenic apolipoprotein), and the ApoB:ApoA-1 ratio integrates both atherogenic and protective particle burdens into a single index that often outperforms traditional ratios. Practitioners use ApoA-1 to assess the adequacy of reverse cholesterol transport, to monitor response to HDL-directed interventions, and to phenotype patients whose lipid patterns do not fit conventional risk models.
What does the ApoA-1 test measure?
Apolipoprotein A-1 is the principal structural and functional protein of high-density lipoprotein (HDL) particles, comprising roughly 70% of HDL protein mass. It serves as the activating cofactor for lecithin-cholesterol acyltransferase (LCAT), the enzyme that esterifies free cholesterol and drives reverse cholesterol transport from peripheral tissues to the liver. Each HDL particle carries two to four ApoA-1 molecules, and plasma ApoA-1 concentration reflects both the number and functionality of these atheroprotective particles.
ApoA-1 is a direct measure of the protein that mediates HDL's cardioprotective functions — reverse cholesterol transport, anti-inflammatory and anti-oxidative effects, and endothelial support. Low ApoA-1 is an independent predictor of coronary artery disease and cardiovascular events, often providing risk discrimination beyond HDL cholesterol concentration alone because HDL-C reflects only the cholesterol cargo whereas ApoA-1 quantifies particle number. It is particularly useful when HDL-C and triglycerides are discordant or when assessing residual risk in patients on lipid-modifying therapy.
Why is the ApoA-1 test ordered?
- Cardiovascular risk assessment in patients with metabolic syndrome, type 2 diabetes, or hypertriglyceridaemia, where HDL-C may underestimate particle number
- Evaluation of patients with low HDL cholesterol to distinguish true HDL deficiency from artefactually low HDL-C due to high triglycerides
- Advanced lipid phenotyping in individuals with premature coronary artery disease or strong family history despite unremarkable standard lipid profiles
- Monitoring residual cardiovascular risk in patients on statin therapy whose LDL-C is at goal but HDL-related risk factors remain
- Investigation of suspected genetic HDL disorders, such as familial hypoalphalipoproteinaemia or Tangier disease, interpreted with HDL-C and genetic testing
- Assessment of patients with chronic inflammatory conditions (rheumatoid arthritis, chronic kidney disease) where HDL function may be impaired despite normal HDL-C
- Adjunct to ApoB measurement and the ApoB:ApoA-1 ratio for comprehensive lipoprotein risk profiling in complex or discordant cases
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
Preferred
Collection method
Venipuncture at patient service centre
Turnaround
3–5 business days
Collection notes
Phlebotomy required; specimen routed to Boston Heart Diagnostics. Fasting for 9–12 hours is preferred to minimise triglyceride interference, though ApoA-1 itself is less affected by postprandial changes than HDL-C. Avoid testing during acute illness or within two weeks of infection, surgery, or major inflammatory events.
Specimen requirements
Minimum 1.0 mL serum (gel separator acceptable). Separate from cells within two hours; ApoA-1 is stable refrigerated for up to one week. Note the performing laboratory and assay platform for serial comparability.
What can affect ApoA-1 results?
ApoA-1 behaves as a negative acute-phase reactant, declining during infection, surgery, or acute inflammatory events; measure after recovery to reflect baseline cardiovascular risk.
Exogenous oestrogen increases hepatic synthesis of ApoA-1 and raises HDL-C, so hormone therapy can shift baseline levels and complicate serial interpretation.
Moderate alcohol intake raises ApoA-1 and HDL-C; chronic heavy consumption can also elevate these markers, confounding their use as pure atheroprotective indices.
Regular physical activity and weight reduction raise ApoA-1, reflecting favourable metabolic adaptation; these lifestyle factors should be stable for serial monitoring.
Fibrates and high-dose niacin increase ApoA-1 and HDL-C; statins have variable effects, so therapy status must be recorded when assessing trends.
ApoA-1 is stable in serum refrigerated for several days, but prolonged storage or freeze-thaw cycles can alter immunoassay results; note the performing laboratory for serial comparability.
What do ApoA-1 results mean?
Elevated
High ApoA-1 is generally atheroprotective and not a clinical concern. Very high concentrations may be seen with hyperalphalipoproteinaemia (often familial, associated with longevity), chronic alcohol use, oestrogen therapy, or fibrate treatment. Isolated elevation warrants clinical correlation but does not typically require intervention.
Normal
Normal ApoA-1 suggests an adequate HDL particle pool for reverse cholesterol transport and atheroprotection. It does not exclude cardiovascular risk from other sources (elevated ApoB, LDL-C, Lp(a), or inflammatory markers), so interpret within the complete lipid and clinical context rather than in isolation.
Reduced
Low ApoA-1 reflects a deficiency of functional HDL particles and is an independent cardiovascular risk factor. Common causes include metabolic syndrome, type 2 diabetes, hypertriglyceridaemia, smoking, sedentary lifestyle, and obesity. Rare genetic disorders (familial hypoalphalipoproteinaemia, LCAT deficiency, Tangier disease) present with very low ApoA-1 and HDL-C; secondary causes should be addressed before attributing low ApoA-1 to primary genetic defects.
Note: ApoA-1 should be measured when the patient is metabolically stable, not during acute illness. It is most informative alongside ApoB, and the ApoB:ApoA-1 ratio may stratify risk better than either alone. Reference intervals differ by laboratory and assay platform, so serial results are best compared within the same performing laboratory. HDL cholesterol and ApoA-1 are correlated but not interchangeable — discordance between the two can reveal metabolically distinct phenotypes.
Frequently asked questions
HDL cholesterol measures the cholesterol cargo carried by HDL particles, whereas ApoA-1 quantifies the protein that forms the particles themselves. ApoA-1 reflects HDL particle number and provides more precise cardiovascular risk assessment, particularly when triglycerides are elevated or HDL-C appears discordant with clinical risk.
How to access the ApoA-1 test
The ApoA-1 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Grundy SM, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. (2019)
- Walldius G, et al. The apoB/apoA-I ratio: a strong, new risk factor for cardiovascular disease and a target for lipid-lowering therapy — a review of the evidence. J Intern Med. (2006)
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiol. (2019)
- Contois JH, et al. Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. Clin Chem. (2009)
- Mach F, et al. 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. (2020)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
cardiovascular
ApoB
The ApoB test measures apolipoprotein B, the structural protein present on all atherogenic lipoproteins (VLDL, IDL, LDL, Lp(a)), providing a direct particle count that is superior to LDL cholesterol for cardiovascular risk stratification, particularly in metabolic syndrome, diabetes, and hypertriglyceridaemia, and guides lipid-lowering therapy intensity and adequacy.
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…